UPDATE 1-Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

March 10 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.